Detection of germline and somatic pathogenic variants in patients with de novo metastatic breast cancer (dnMBC) and assessment of their prognostic relevance: A Hellenic Cooperative Oncology Group (HeCOG) translational cohort study

2025·

E. Fountzilas

,

K. Papadopoulou

Nikolaos Korfiatis

,

A. Goussia

,

A. Christopoulou

,

E. Moirogiorgou

,

N. Tsoukalas

,

G. Petrakis

,

C. Gouedard

,

F. Zagouri

,

D. Stefanou

,

F. Kyriakou

,

E. Vorrias

,

S. Karageorgopoulou

,

F. Dimitrakopoulos

,

A. Vernadou

,

S. Murray

,

G. Fountzilas

NCT05758948 Cite DOI

Conference Paper Clinical Trial

Authors

Nikolaos Korfiatis

Professor of Data Management and Analytics

Professor of Data Management and Analytics at the Department of Informatics, Ionian University, Corfu. Senior Statistician of the Hellenic Cooperative Oncology Group (HeCOG).

---

← Clinico-pathological and genomic features of HER2-low early Breast Cancer (eBC). Results of retrospective analysis of seven adjuvant trials by the Hellenic Cooperative Oncology Group (HeCOG) 2025

Frequency of Adverse Events Reported Digitally by Patients with Advanced NSCLC: Analysis From CLIMEDIN, a HeCOG Study 2025 →